EUVIMEDEUVIMED entdecken
Crossref

Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora® 30 ‍mg Syringes for S.C. Injection), the first Nanobody® compound in Japan

Masafumi Kawanishi, Yasuyuki Fujii

Folia Pharmacologica Japonica · 2023

DOI: 10.1254/fpj.23051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Pharmacologica Japonica, 2023. Verfasst von Masafumi Kawanishi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Development Headquarters, Pharmaceutical Product, Taisho Pharmaceutical Co., Ltd. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, RheumatoidHumansAnimalsMiceTumor Necrosis Factor-alphaMethotrexateJapanSyringesAntibodies, Monoclonal, HumanizedReceptors, Tumor Necrosis FactorAntibodies, MonoclonalInfliximabTreatment OutcomeInflammation

Substanzen

Tumor Necrosis Factor-alphaMethotrexateAntirheumatic AgentsAntibodies, Monoclonal, HumanizedReceptors, Tumor Necrosis FactorAntibodies, MonoclonalInfliximab

Autor:innen und Institutionen

  • Development Headquarters, Pharmaceutical Product, Taisho Pharmaceutical Co., Ltd.
  • Research Headquarters, Pharmaceutical Product, Taisho Pharmaceutical Co., Ltd.

Zitieren

APA

Kawanishi, M., & Fujii, Y. (2023). Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora® 30 ‍mg Syringes for S.C. Injection), the first Nanobody® compound in Japan. Folia Pharmacologica Japonica. https://doi.org/10.1254/fpj.23051

Vancouver

Kawanishi M, Fujii Y. Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora® 30 ‍mg Syringes for S.C. Injection), the first Nanobody® compound in Japan. Folia Pharmacologica Japonica. 2023. doi:10.1254/fpj.23051

BibTeX
@article{Kawanishi2023,
  author = {Kawanishi, Masafumi and Fujii, Yasuyuki},
  title = {Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora® 30 ‍mg Syringes for S.C. Injection), the first Nanobody® compound in Japan},
  journal = {Folia Pharmacologica Japonica},
  year = {2023},
  doi = {10.1254/fpj.23051}
}
Kostenlos starten →